Overview

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Status:
RECRUITING
Trial end date:
2026-03-15
Target enrollment:
Participant gender:
Summary
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
The Children's Hospital of Zhejiang University School of Medicine
Collaborator:
Leman Biotech Co., Ltd.